Supplementary Methods from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer

This is a Experimental Study study.

Key Points

Inhibition of EZH2 through PI3K-mTOR pathways aims to reduce metastasis in triple-negative breast cancer.
Targeting both EZH2 and PI3K-mTOR may improve response to immunotherapy in resistant cases.
The methods outline new therapeutic strategies for overcoming challenges in treating triple-negative breast cancer.
These approaches could pave the way for enhanced treatment options in patients facing metastasis.

We only have this paper's title and publication details.

Supplementary methods detail how inhibiting EZH2 via PI3K–mTOR impacts immunotherapy and metastasis resistance in triple-negative breast cancer.

Supplementary Methods to accompany manuscript

No takes yet. Share an insight, caveat, or question.

Melino et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share